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Abstract
Background: Progress towards the development of a malaria vaccine against Plasmodium vivax, the most widely
distributed human malaria parasite, will require a better understanding of the immune responses that confer
clinical protection to patients in regions where malaria is endemic.
Methods: Glutathione S-transferase (GST) and GST-fusion proteins representing the N- terminus of the merozoite
surface protein 1 of P. vivax, PvMSP1-N, and the C-terminus, PvMSP1-C, were covalently coupled to BioPlex
carboxylated beads. Recombinant proteins and coupled beads were used, respectively, in ELISA and Bioplex assays
using immune sera of P. vivax patients from Brazil and PNG to determine IgG and subclass responses.
Concordances between the two methods in the seropositivity responses were evaluated using the Kappa statistic
and the Spearman’s rank correlation.
Results: The results using this methodology were compared with the classical microtitre enzyme-linked
immnosorbent assay (ELISA), showing that the assay was sensitive, reproducible and had good concordance with
ELISA; yet, further research into different statistical analyses seems desirable before claiming conclusive results
exclusively based on multiplex assays. As expected, results demonstrated that PvMSP1 was immunogenic in natural
infections of patients from different endemic regions of Brazil and Papua New Guinea (PNG), and that age
correlated only with antibodies against the C-terminus part of the molecule. Furthermore, the IgG subclass profiles
were different in these endemic regions having IgG3 predominantly recognizing PvMSP1 in Brazil and IgG1
predominantly recognizing PvMSP1 in PNG.
Conclusions: This study validates the use of the multiplex assay to measure naturally-acquired IgG antibodies
against the merozoite surface protein 1 of P. vivax.
Background
Plasmodium vivax is the most widely distributed human
malaria parasite and responsible for 100-300 million
clinical cases each year including severe disease and
death [1]. Studies on naturally acquired immune
responses against different P. vivax antigens, including,
among others, merozoite surface antigens, Duffy-binding
protein, circumsporozoite surface protein, apical
membrane 1, have demonstrated their immunogenicity
in natural infections [2-6]. In addition, some of these
studies have also demonstrated differences in acquisi-
tiuon of IgG subclasses against particular antigens. The
association of clinical protection with specific antigens
of P. vivax, however, has been reported in only two pro-
spective cohort longitudinal studies [7,8]. In the first,
clinical protection was associated with IgG3 antibodies
against the N-terminus of the merozoite surface protein
1 (PvMSP1) in residents of the Brazilian Amazon region
of Portuchuelo [7]. In the second, clinical protection
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This latter study used a functional assay on naturally-
acquired binding inhibitory antibodies against the Duffy-
binding protein region II (PvDBPII) to demonstrate the
association of these antibodies with protection against P.
vivax infection.
Antibodies in these studies were measured using the
ELISA assay [9], a technique requiring high amounts of
coating-antigens and immune sera when large numbers
of samples must be screened. To overcome these limita-
tions, suspension array technologies with high-through-
put capacity to simultaneously analyse several proteins
with minimal amount of immune sera have been devel-
oped [10]. Recently, these methodologies have been
reported to measure antibodies to multiple malaria vac-
cine candidate antigens [11], to measure simultaneously
antibody recognition of twenty eight Plasmodium falci-
parum erythrocyte membrane protein 1 (PfEMP1)
domains [12], and to develop a high throughput func-
tional assay to study binding of ICAM1 to the 3D7
strain PfEMP1 repertoire [13].
The aim of this study was to measure naturally
acquired IgG anti-PvMSP1 antibodies in human patients
infected with P. vivax from different endemic regions of
Brazil and Papua New Guinea through implementation
and validation of the BioPlex suspension array system.
Methods
Human samples and study areas
Human plasma samples were obtained from different
endemic areas of Brazil and PNG and one control group
from a non-endemic region. One group comprised 87
adults who participated of a cross-sectional survey at
riverine communities from Rio Machado in the Brazilian
Amazon [14]. The other group consisted of 122 children
from Madang and Maprik in Papua New Guinea who
presented to local Health Centers (with a median age of
30.5 months and age range from three to 72 months).
One hundred human plasma samples were used to ana-
lyse the concordance between the BioPlex assay and
ELISA. The remaining samples were used to measure
IgG isotypes. Control subjects consisted of 16 healthy
adult volunteers living in the city of Barcelona (Spain)
that never have been exposed to malaria or visited
malaria endemic regions. These studies received the
ethical approval of Local Institutional Reviewing Boards.
Recombinant antigens
Glutathione S-transferase (GST) and GST-fusion pro-
teins representing the N- terminus, PvMSP1-N, and the
C-terminus, PvMSP1-C, have already been described
[2,15]. GST and GST-fusion proteins were purified on
glutathione-Sepharose 4B (GE healthcare), and protein
concentration was determined by Bradford assay (Bio-
Rad).
Covalent coupling of recombinant proteins to beads
BioPlex carboxylated beads (Bio-Rad) were covalently
coated with the different recombinant proteins following
the manufacturer’si n s t r u c t i o n s( B i o P l e xA m i n eC o u -
pling Kit). Briefly, activated beads (1.25 × 10
6 beads/ml)
were resuspended in 100 μlo fP B Sa n d1μg of each
recombinant protein used per coupling reaction. Incuba-
tion under rotation was done at 4°C overnight and
coupled beads were washed with 500 μl of PBS pH 7.4.
After re-suspending coupling beads in 250 μlo fb l o c k -
ing buffer and further incubation under rotation at
room temperature for 30 min, beads were washed with
500 μl of storage buffer and centrifuged for six minutes
at 14,000 × g. Pellets were ressuspended into 125 μlo f
the same buffer and stored at 4°C protected from light
until use.
Analysis of coupled beads on the BioPlex system
Coupled beads were analysed as described in Cham et al
[12] with modifications. Briefly, aliquots of 50 μl, corre-
sponding to 5,000 coated beads were used for each assay.
Frozen plasma samples were thawed at room tempera-
ture, diluted 1:50 in assay buffer and 50 μl aliquots added
to the beads (final plasma dilution 1:100). Aliquots of 50
μlo fB i o t i n y l a t e dh u m a nI g Ga ntibody (Sigma) diluted
1:7,500 and of phycoerythrin conjugated streptavidin
diluted to 2 μg/ml were used in subsequent incubations.
Beads were re-suspended in 125 μl of assay buffer
(BioRad) and analysed on the BioPlex100 system and
results were expressed as median fluorescent intensity
(MFI). The BioPlex assay to detect IgG subclasses was
performed as described previously using specific biotiny-
lated human IgG isotypes (Sigma) diluted 1:5,000 in
assay buffer. Specifically, monoclonal anti-human IgG1
clone 8c/6-39, monoclonal anti-human IgG2 clone HP-
6014, monoclonal anti-human IgG3 clone HP-6050 and
monoclonal anti-human IgG4 clone HP-6025 were used.
Enzyme-linked immunosorbent assay (ELISA)
Human IgG antibodies against GST and GST-PvMSP1
tags were detected by ELISA as described [2]. Plates
were coated with 100 ng/well of each protein. The
OD492 values to each recombinant protein were
o b t a i n e db ys u b t r a c t i n gt h eO D 4 9 2v a l u e so ft h es a m e
serum to GST alone. Cut-off points were set at three
standard deviations above the mean OD492 of sera from
16 individuals, unexposed to malaria, from the city of
Barcelona.
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Non-parametric test (Fisher exact and Wilcoxon Rank
Sum) were carried out to test differences with response
variable when appropriate. Univariate and multivariate
logistic regression were adjusted to analyse the relation-
ship on the seropositivity of PvMSP1-C or PvMSP1-N
measured by ELISA or BioPlex techniques. Correlation
among variables was evaluated with Spearman’sr a n k
correlation.
Concordances between the two methods in the sero-
positivity responses were evaluated using the Kappa sta-
tistic. Good agreement was defined as kappa-value > 0.6,
according to [16]. All the tests were performed using a
two-sided significance level of 0.05. The analysis was
performed using STATA version 9.2 (StataCorp., Col-
lege Station, TX, USA).
Results
Concordance between the BioPlex assay and ELISA
Three recombinant proteins corresponding to GST and
GST-fused to the N- and C-termini of PvMSP1 were used
for this analysis. Plasma samples from 87 adults from Bra-
zil as well as from 100 children from PNG were tested at
1:100 dilutions to measure total IgG antibodies. Concor-
dance between the BioPlex and ELISA assays was evalu-
ated using the Kappa statistics. Kappa values presented
good agreement for the samples from Madang and for
both recombinant proteins, PvMSP1-N (Kappa = 0.638
and total agreement = 83%) and PvMSP1-C (Kappa =
0.758 and total agreement = 88%) (Figure 1). The concor-
dance of both techniques using sera from Rio Machado
was lower for both molecules, PvMSP1-N (Kappa = 0.163
and total agreement = 78%) and PvMSP1-C (Kappa =
0.366 and total agreement = 72%) (Figure 1).
Concordance between BioPlex and ELISA assay was
also evaluated with Spearman’s rank correlation (Figure
2). The Spearman’s rank correlation coefficients (Rho)
for the samples from Madang were respectively 80.5%
and 86.8% for PvMSP1-N and PvMSP1-C. The Spear-
man’s rank correlation coefficients (Rho) for the samples
from Rio Machado was lower for PvMSP1-N with a Rho
= 34.4%, and for PvMSP1-C with a Rho = 71.8%. In
spite of these different values, correlations were signifi-
cant (p = 0.005) for all comparisons.
Detection of total IgG antibodies to PvMSP1 by BioPlex
assay and association with risk factors
Percentage of individuals from Madang and Rio
Machado containing naturally-acquired IgG antibodies
against PvMSP1 are presented in Table 1. IgG antibo-
dies to PvMSP1-N and PvMSP1-C were detected,
respectively, in 31 (31%) and 52 (52%) (Madang) and
77 (89%) and 70 (80%) (Rio Machado). When groups
were divided into symptomatic, asymptomatic and
Figure 1 Diagram representing the concordance between BioPlex and ELISA assays.
Fernandez-Becerra et al. Malaria Journal 2010, 9:29
http://www.malariajournal.com/content/9/1/29
Page 3 of 8non-infected individuals (defined as subjects with no
symptoms, negative microscopy and/or negative PCR),
15/50 (30%) and 8/9 (89%) of symptomatic patients
from Madang and Rio Machado contained, respec-
tively, anti-PvMSP1-N antibodies whereas 28/50 (56%)
f r o mM a d a n ga n d9 / 9( 1 0 0 % )f r o mR i oM a c h a d o
reacted against PvMSP1-C. Furthermore, 7/20 (35%)
and 38/42 (90%) of asymptomatic patients from
Madang and Rio Machado recognized, respectively,
PvMSP1-N whereas 12/20 (60%) and 30/42 (71%)
reacted against PvMSP1-C. Of importance, a high
number of non-infected patients, 9/30 (30%) from
Madang and 31/36 (86%) from Rio Machado contained
specific anti-PvMSP1-N antibodies and 12/30 (40%)
from PNG and 31/36 (86%) from Rio Machado antibo-
dies against PvMSP1-C.
Univariate and multivariate logistic regressions analy-
sis showed that, excepting for age, no other variable was
significantly associated with anti-PvMSP1 antibodies
(Table 2). Interestingly, age was only associated with
antibodies against the C-terminus but not the N-termi-
nus in both areas. Moreover, in Rio Machado the asso-
ciation was observed in older people (positive
individuals mean age = 32 years, negative individuals
mean age = 23 years), whereas in PNG was observed in
younger children (positive individuals mean age = 27
months; negative individuals mean age = 37 months).
Prevalence of IgG subclasses
To analyse the IgG subclass antibody responses to
PvMSP1, 42 plasma samples from Brazil and 42 from
PNG were selected. Samples from Brazil included
asymptomatic patients (29/42) as previous results had
already investigated their IgG isotype profiles [7].
Remaining samples from Brazil and PNG were randomly
chosen. Results demonstrated that children from PNG
Figure 2 Correlation between the results from BioPlex and ELISA using the Spearman’s rank correlation test. Rho: Spearman’sr a n k
correlation coefficient, MFI (BioPlex): median fluorescent intensity and OD (ELISA): Optical density.
Table 1 Percentage of individuals positive for IgG
antibodies to PvMSP1 N- and C-termini in samples from
PNG (Madang) and Brazil (Rio Machado) obtained by
BioPlex assay.
Samples from Madang
n = 100
Samples from Rio
Machado
n=8 7
Rec. protein Classification Classification
PvMSP1-N 31 (31%) S 15/50 (30%) 77 (89%) S 8/9 (89%)
AS 7/20 (35%) AS 38/42 (90%)
N.I. 9/30 (30%) N.I. 31/36 (86%)
PvMSP-C 52 (52%) S 28/50 (56%) 70 (80%) S 9/9 (100%)
AS 12/20 (60%) AS 30/42 (71%)
N.I. 12/30 (40%) N.I 31/36 (86%)
S (symptomatic patients), AS (asymptomatic patients), N.I. (not infected).
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(82%) and lower percentages of IgG3 and IgG4 (close to
40%) to both N- and C-termini of PvMSP1 (Figure 3A),
whereas adults from Brazil contained predominantly
IgG3 antibodies to the N- and C-termini of PvMSP1
(close to 60%) (Figure 3B). None of the variables studied
was significantly associated with any one particular IgG
isotype.
Discussion
The use of multiplex assays has not been reported for P.
vivax antigens and, therefore, a comparison of the Bio-
Plex assay values with those obtained by ELISA was
initially made to determine the concordance and corre-
lation of these techniques. To do so, two different statis-
tics, the Kappa statistics and the Spearman’sr a n k
correlation test, were used. Kappa Statistics has been
proposed as the most appropriate method when the
same parameter with two similar techniques is com-
pared [16]. The coefficient correlation tests, such as
Spearman’s rank correlation or Pearson correlation, has
been used to validate multiplex assays in P. falciparum
and other diseases [11,12,17]. Using Kappa statistics, a
good agreement, with significant values, was obtained
for both recombinant proteins with the samples from
PNG. In contrast, even if the agreement of the results
obtained from Brazil was above 70%, Kappa values were
not significant. Most of the discrepancy, however, was
the result of samples slightly positive by BioPlex and
negative by ELISA. In addition, the Spearman’sr a n k
correlation test demonstrated significant correlations for
all comparisons (Figure 2). As this correlation has been
used to validate the use of multiplex assays in P. falci-
parum and other diseases, the data from Brazil remain
meaningful; yet, it also argues that further research into
different statistical analyses is desirable before claiming
conclusive results exclusively based on multiplex assays.
Naturally-acquired IgG responses against PvMSP1
have demonstrated that a large proportion of individuals
expose to P. vivax contain IgG antibodies against differ-
ent regions of the molecule [15,18,19]. The results
obtained with the BioPlex assay with subjects from Bra-
zilian adults and PNG children confirm these findings
even though a lower overall response to PvMSP1 was
observed in PNG children (Table 1). Interestingly, non-
infected individuals (no symptoms, negative microscopy
and/or negative PCR) from both regions contained anti-
bodies against PvMSP1. This data indicate that anti-
Table 2 Results of the multilevel logistic regression model showing different variables and their association with IgG
antibodies to PvMSP1 N- and C- termini in samples from Brazil (Rio Machado) and Papua New Guinea (Madang).
Samples from Rio Machado Samples from Madang
Variable OR 95%CI p-value OR 95%CI p-value
PvMSP N-terminus
Classification
Non infected 1 1 (1.00-1.08)
Symptomatic 1.29 (0.13-12.66) 1.00 (0.37-2.69)
Asymptomatic 1.53 (0.38-6.20) 0.835 1.26 (0.38-4.20) 0.911
Sex
Female 1
Male 0.26 (0.05-1.27) 0.096 n.d
Age (years)
Unit increment 1.04 (0.99-1.10) 0.113 1.01 (0.98-1.03) 0.607
PvMSP1C-terminus
Classification
Non infected 1 1
Asymptomatic 0.40 (0.13-1.28) 1.24 1.91 (0.76-4.79)
Symptomatic 2.25 (0.71-7.14) 0.283
Sex
Female 1
Male 1.65 (0.60-4.55) 0.336 n.d
Age
Unit increment 1.04 (1.00-1.08) 0.046 0.97 (0.95-0.99) 0.013
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individuals presented a sub-patent parasitaemia, not
detected by microscopy or PCR, representing undetected
carriers. Both explanations have supporting evidence as
anti-PvMSP1 antibodies have been reported to last up-
to 30 years [20] and direct mosquito feeding of patients
with sub-patent vivax infections have successfully trans-
mitted P. vivax to mosquitoes [21]. Determining their
frequencies will have implications for malaria control
programmes in these regions.
Studies on naturally acquired immunity in P. vivax in
PNG have shown that it is acquired in children below
nine years of age [22], while acquired immunity in Brazil
is only reached later, when closer to 15-20 years old in
native populations [7] and also in migrant adult working
populations [18]. Interestingly, age was significantly
associated with the response to PvMSP1-C and not to
PvMSP1-N in both regions; yet, in PNG this association
was mainly observed in younger children (positive indi-
viduals mean age = 27 months, negative individuals
mean age = 37 months) whereas in Brazil was observed
in older populations (positive individuals mean age = 32
years, negative individuals mean age = 23 years). Further
prospective studies with larger sample sizes are required
t od e t e r m i n et h er o l e ,i fa n y ,o fP v M S P 1i na g e - d e p e n -
dent acquisition of immunity.
Figure 3 IgG subclass profiles against PvMSP1-N and PvMSP1-C. A. Percentage of IgG subclass responses in Madang/Maprik (PNG). B.
Percentage of IgG subclass responses in Rio Machado (Brazil).
Fernandez-Becerra et al. Malaria Journal 2010, 9:29
http://www.malariajournal.com/content/9/1/29
Page 6 of 8This is the first study that uses the BioPlex system to
measure IgG subclasses in malaria. To validate its use,
sera from asymptomatic patients from Brazil were cho-
s e na sp r e v i o u ss t u d i e sh a dd e m o n s t r a t e dt h a tt h e s e
patients contained predominantly IgG3 antibodies
against PvMSP1-N [7]. As expected, IgG3 anti-PvMSP1-
N antibodies were the predominant isotype in asympto-
matic patients from Rio Machado. Remaining IgG pro-
files were very much in agreement with previous studies
using ELISA in which IgG1 and IgG3 cytophilic isotypes
are the predominant isotypes against PvMSP1 with low
or undetectable levels of IgG2 and IgG4 [19,23]. Inter-
estingly, IgG isotype profiles of PNG and Brazil were
different with a predominance of IgG1 antibodies
against PvMSP1 in PNG and a predominance of IgG3
antibodies against PvMSP1 in Brazil. Here again,
whether this result is due to the difference in the age
groups, remains to be determined in larger surveys from
these regions including all age-groups.
Conclusions
Several studies on naturally acquired IgG responses
against different P. vivax antigens have been described
using the ELISA assay. The BioPlex assay described and
validated here is the first to measure naturally acquired
humoral IgG antibody responses against a P. vivax anti-
gen and the first one to study IgG subclasses in malaria.
These studies compared the naturally acquired humoral
IgG responses against PvMSP1 in different endemic
regions of Brazil and PNG. Results demonstrated differ-
ences in percentage of responders, differences between
the age correlating to responses and differences on iso-
type profiles. Whether these differences are due to the
limited power of this study, which was mainly designed
to validate the use of the multiplex assay for PvMSP1,
or to real differences in the immunoepidemiology of P.
vivax in these endemic regions, is presently under inves-
tigation. Most relevant, prospective comparative longitu-
dinal cohort studies in endemic different regions using
the BioPlex assay can now be envisaged to look for asso-
ciations against infection and clinical protection having
clear implications in antigen discovery and vaccine
development for P. vivax.
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